Vincenzo Morra-Brescia

Naples, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 236 publications

Profiling the long-term risk of severe adverse events in a cohort of multiple sclerosis patients treated with different treatment sequences: Results from the Italian Multiple Sclerosis and Related Disorders Registry (I-MS&RD) (ProSA study).

Profiling the long-term risk of severe adverse events in a cohort of multiple sclerosis patients treated with different treatment sequences: Results from the Italian Multiple Sclerosis and Related Disorders Registry (I-MS&RD) (ProSA study).

Journal: Multiple sclerosis (Houndmills, Basingstoke, England)

Published: July 04, 2026

Real-world analytical and clinical evaluation of the Siemens Atellica® immunoassay for plasma neurofilament light chain in multiple sclerosis.

Real-world analytical and clinical evaluation of the Siemens Atellica® immunoassay for plasma neurofilament light chain in multiple sclerosis.

Journal: Multiple sclerosis and related disorders

Published: April 19, 2026

Subcutaneous natalizumab administration in relapsing-remitting multiple sclerosis: results of EASIER 2 study.

Subcutaneous natalizumab administration in relapsing-remitting multiple sclerosis: results of EASIER 2 study.

Journal: Journal of neurology

Published: March 19, 2026

Passive digital monitoring via mobile apps and wearables in multiple sclerosis: A systematic review.

Passive digital monitoring via mobile apps and wearables in multiple sclerosis: A systematic review.

Journal: Revue neurologique

Published: March 06, 2026

Subcutaneous Ocrelizumab for the Treatment of Relapsing Forms of Multiple Sclerosis: A Budget Impact Model.

Subcutaneous Ocrelizumab for the Treatment of Relapsing Forms of Multiple Sclerosis: A Budget Impact Model.

Journal: PharmacoEconomics - open

Published: February 16, 2026

Ocrelizumab in early relapsing-remitting multiple sclerosis: first interim analysis of the MUSPO Italian prospective cohort.

Ocrelizumab in early relapsing-remitting multiple sclerosis: first interim analysis of the MUSPO Italian prospective cohort.

Journal: Journal of neurology

Published: February 12, 2026

Theory of mind in adults with pediatric onset multiple sclerosis: neuropsychological, emotional, and quality of life correlates.

Theory of mind in adults with pediatric onset multiple sclerosis: neuropsychological, emotional, and quality of life correlates.

Journal: Multiple sclerosis and related disorders

Published: January 20, 2026

Effect of dynamics and timing of SARS-CoV-2 vaccination on immune response in people with multiple sclerosis during cladribine treatment.

Effect of dynamics and timing of SARS-CoV-2 vaccination on immune response in people with multiple sclerosis during cladribine treatment.

Journal: Clinical immunology (Orlando, Fla.)

Published: December 29, 2025

Dysarthria assessment in multiple sclerosis patients.

Dysarthria assessment in multiple sclerosis patients.

Journal: Multiple sclerosis (Houndmills, Basingstoke, England)

Published: December 20, 2025

HerMeS: a registry-based evaluation of the HERCULES criteria for identifying nonrelapsing SPMS.

HerMeS: a registry-based evaluation of the HERCULES criteria for identifying nonrelapsing SPMS.

Journal: Journal of neurology

Published: December 05, 2025

Disability Worsening Phenotypes in Multiple Sclerosis and Impact of Disease-Modifying Treatments.

Disability Worsening Phenotypes in Multiple Sclerosis and Impact of Disease-Modifying Treatments.

Journal: Neurology

Published: November 24, 2025

Comparative Effectiveness of Cladribine and S1P Receptor Modulators in Treatment-Naive Relapsing-Remitting MS.

Comparative Effectiveness of Cladribine and S1P Receptor Modulators in Treatment-Naive Relapsing-Remitting MS.

Journal: JAMA network open

Published: November 03, 2025

Showing 1-12 of 236

Last Updated: 09/26/2026